EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudie

Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial

Naokatsu Ando iD, Daisuke Mizushima, Kazumi Omata, Takashi Nemoto, Natsumi Inamura, Saori Hiramoto, Misao Takano, Takahiro Aoki, Koji Watanabe iD, Haruka Uemura, Daisuke Shiojiri, Yasuaki Yanagawa iD und 5 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad278 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Naokatsu Ando und 16 weiteren Autor:innen. Beteiligte Einrichtung: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: HIV Infections, Syphilis, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Center for Global Health and Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Amoxicillin plus probenecid is an alternative to intramuscular benzathine penicillin G for treating syphilis in the United Kingdom. Low-dose amoxicillin is an alternative treatment option used in Japan.

Methods

We conducted an open-label, randomized, controlled, non-inferiority trial between 31 August 2018, and 3 February 2022, to compare 1500 mg low-dose amoxicillin monotherapy with the combination of 3000 mg amoxicillin and probenecid (non-inferiority margin 10%). Patients with human immunodeficiency virus (HIV) infection and syphilis were eligible. The primary outcome was the cumulative serological cure rate within 12 months post-treatment, measured using the manual rapid plasma reagin card test. Secondary outcomes included safety assessment.

Results

A total of 112 participants were randomized into 2 groups. Serological cure rates within 12 months were 90.6% and 94.4% with the low-dose amoxicillin and combination regimens, respectively. Serological cure rates for early syphilis within 12 months were 93.5% and 97.9% with the low-dose amoxicillin and combination regimens, respectively. Non-inferiority of low-dose amoxicillin compared with amoxicillin plus probenecid overall and for early syphilis was not confirmed. No significant side effects were detected.

Conclusions

This is the first randomized controlled trial to demonstrate a high efficacy of amoxicillin-based regimens for treating syphilis in patients with HIV infection, and the non-inferiority of low-dose amoxicillin compared with amoxicillin plus probenecid was not seen. Therefore, amoxicillin monotherapy could be a good alternative to intramuscular benzathine penicillin G with fewer side effects. However, further studies comparing with benzathine penicillin G in different populations and with larger sample sizes are needed. Trials Registration (UMIN000033986).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsSyphilisDrug-Related Side Effects and Adverse ReactionsHumansAmoxicillinPenicillin G BenzathineAnti-Bacterial AgentsHIVProbenecid

Stichwörter der Autor:innen

Treponema pallidumamoxicillinhuman immunodeficiency virussyphilis

Substanzen

AmoxicillinPenicillin G BenzathineAnti-Bacterial AgentsProbenecid

Autor:innen und Institutionen

  • AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Department of Laboratory, National Center for Global Health and Medicine, Tokyo, Japan.

ORCID-Profile: Naokatsu Ando, Koji Watanabe, Yasuaki Yanagawa

Förderung

  • National Center for Global Health and Medicine

Zitieren

APA

Ando, N., Mizushima, D., Omata, K., Nemoto, T., Inamura, N., Hiramoto, S., Takano, M., Aoki, T., Watanabe, K., Uemura, H., Shiojiri, D., Yanagawa, Y., Tanuma, J., Teruya, K., Kikuchi, Y., Gatanaga, H., & Oka, S. (2023). Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad278

Vancouver

Ando N, Mizushima D, Omata K, Nemoto T, Inamura N, Hiramoto S, et al. Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad278

BibTeX
@article{Ando2023,
  author = {Ando, Naokatsu and Mizushima, Daisuke and Omata, Kazumi and Nemoto, Takashi and Inamura, Natsumi and Hiramoto, Saori and Takano, Misao and Aoki, Takahiro and Watanabe, Koji and Uemura, Haruka and Shiojiri, Daisuke and Yanagawa, Yasuaki and Tanuma, Junko and Teruya, Katsuji and Kikuchi, Yoshimi and Gatanaga, Hiroyuki and Oka, Shinichi},
  title = {Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad278}
}
Kostenlos starten →